Clinical Trials Logo

Restless Legs Syndrome clinical trials

View clinical trials related to Restless Legs Syndrome.

Filter by:

NCT ID: NCT00806026 Completed - Clinical trials for Idiopathic Restless Legs Syndrome

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

RLS
Start date: December 2008
Phase: Phase 3
Study type: Interventional

This purpose of this study is to investigate the efficacy and tolerability of pregabalin in treating idiopathic RLS patients for up to 12 months.

NCT ID: NCT00748098 Completed - Clinical trials for Restless Legs Syndrome

Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance

Start date: October 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of GSK1838262 extended release tablets in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance.

NCT ID: NCT00721279 Completed - Clinical trials for Restless Legs Syndrome

Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome

Start date: September 2007
Phase: N/A
Study type: Observational

The objectives of the Post Market Surveillance (PMS) study are to evaluate the treatment effect of pramipexole on Restless Legs Syndrome (RLS) severity as measured by International Restless Legs Rating Scale and Global Clinical Impression - Improvement, to evaluate the time to reaching maintenance dose of pramipexole

NCT ID: NCT00685815 Completed - Restless Legs Clinical Trials

Intravenous Iron Metabolism in Restless Legs Syndrome

Start date: November 2006
Phase: Phase 2
Study type: Interventional

To determine the effects of high-dose infusions of iron on Restless Legs Syndrome (RLS) symptoms and brain concentrations of iron.

NCT ID: NCT00676403 Completed - Clinical trials for Restless Legs Syndrome

Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients

Start date: April 2008
Phase: Phase 2
Study type: Interventional

To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients

NCT ID: NCT00674310 Completed - Parkinson's Disease Clinical Trials

A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions

Start date: February 2004
Phase: N/A
Study type: Interventional

The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole tablets,0.25 mg, to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fed conditions using a single dose, randomized, 2-treatment, 2-period, 2-sequence cross-over design.

NCT ID: NCT00673088 Completed - Parkinson's Disease Clinical Trials

A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions

Start date: February 2004
Phase: N/A
Study type: Interventional

The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole Tablets, 0.25 mg to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence cross-over design.

NCT ID: NCT00666965 Completed - Clinical trials for Idiopathic Restless Legs Syndrome

A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients

Start date: June 2008
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to investigate efficacy and safety of SPM 962 in Japanese RLS patients in a multi-center, placebo-controlled double-blind parrallel group comparative study following once-daily multiple transdermal doses of SPM 962 within a range of 2.25 to 6.75 mg/day. Recommended maintainance dose range is also to be investigated.

NCT ID: NCT00656110 Recruiting - Clinical trials for Restless Legs Syndrome

Neuroma Injections to Treat Restless Legs Syndrome - RCT

Start date: April 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether, in a randomized, placebo-controlled trial, restless legs syndrome (RLS) can be caused by pinched and damaged foot nerves called neuromas.

NCT ID: NCT00654498 Completed - Clinical trials for Restless Legs Syndrome

Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)

Start date: April 2008
Phase: Phase 3
Study type: Interventional

To determine efficacy and safety of Pramipexole 0.125mg to 0.75mg daily for 6 weeks compared to placebo in the treatment of idiopathic Restless Legs Syndrome (RLS)